Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a report by Anthony McDonnell and a team led by the Center for Global Development in which they created economic estimates of the costs/values of action (and inaction) through 2050, based on 5 possible action/ inaction scenarios.
Dear All, With thanks to alert reader Liam Sharkey, a post-doc in Melbourne, for the heads-up on this topic, I am very pleased to see the 17 June 2025 report from Australia entitled “Fighting Superbugs: A Subscription-Style Reimbursement Mechanism to Boost Australia’s Arsenal of Antimicrobial Medicines.” This paper is the output from a Nov 2024 roundtable in Canberra
Dear All, As a follow-on to the global commitments made during the 2024 UN General Assembly High-Level Meeting on AMR (UNGA 2024 HLM AMR), the Global Future Council on AMR of the World Economic Forum (WEF) authored the 2025 Davos Compact on AMR with review by the Quadripartite Joint Secretariate on AMR as a way for organizations to
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), In the wake of the Sep 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR), it has been encouraging to see the continued discussion around Push and Pull incentives for antibacterial innovation and access (see the AMR.Solutions post-UNGA webpage for
Dear All, I have just learned that in parallel with the 26 Sep 2024 High-Level Meeting on AMR at the UN General Assembly, a day of virtual advocacy in support of PASTEUR is being organized by The Infectious Diseases Society of America, BIO, Cystic Fibrosis Foundation, Partnership to Fight Infectious Diseases, and The Pew Charitable
Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We wrote previously in (i) the 7 Dec 2023 newsletter (“How Italy should Push and Pull: New report as Italy takes the 2024 G7 chair”), (ii) the 17 Oct 2024 newsletter (“Italy funds CARB-X and announces pull incentive!”), and finally (iii) the 9 Jan
Dear All, BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I’ve never seen one before, but an SSN is market research with which BARDA will “collect feedback from current and prospective antibiotic development partners” that will “serve as continued market research for potential future acquisitions
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA). The broad idea is the
Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano